No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. / Svane, Maria S.; Johannesen, Helle H.; Martinussen, Christoffer; Bojsen-Moller, Kirstine N.; Hansen, Martin Lundsgaard; Hansen, Adam E.; Deacon, Carolyn F.; Hartmann, Bolette; Keller, Sune H.; Klausen, Thomas L.; Loft, Annika; Kjaer, Andreas; Madsbad, Sten; Lofgren, Johan; Holst, Jens J.; Wewer Albrechtsen, Nicolai J.

In: Diabetes, Obesity and Metabolism, Vol. 22, No. 10, 2020, p. 1837-1846.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Svane, MS, Johannesen, HH, Martinussen, C, Bojsen-Moller, KN, Hansen, ML, Hansen, AE, Deacon, CF, Hartmann, B, Keller, SH, Klausen, TL, Loft, A, Kjaer, A, Madsbad, S, Lofgren, J, Holst, JJ & Wewer Albrechtsen, NJ 2020, 'No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes', Diabetes, Obesity and Metabolism, vol. 22, no. 10, pp. 1837-1846. https://doi.org/10.1111/dom.14106

APA

Svane, M. S., Johannesen, H. H., Martinussen, C., Bojsen-Moller, K. N., Hansen, M. L., Hansen, A. E., Deacon, C. F., Hartmann, B., Keller, S. H., Klausen, T. L., Loft, A., Kjaer, A., Madsbad, S., Lofgren, J., Holst, J. J., & Wewer Albrechtsen, N. J. (2020). No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes, Obesity and Metabolism, 22(10), 1837-1846. https://doi.org/10.1111/dom.14106

Vancouver

Svane MS, Johannesen HH, Martinussen C, Bojsen-Moller KN, Hansen ML, Hansen AE et al. No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes, Obesity and Metabolism. 2020;22(10):1837-1846. https://doi.org/10.1111/dom.14106

Author

Svane, Maria S. ; Johannesen, Helle H. ; Martinussen, Christoffer ; Bojsen-Moller, Kirstine N. ; Hansen, Martin Lundsgaard ; Hansen, Adam E. ; Deacon, Carolyn F. ; Hartmann, Bolette ; Keller, Sune H. ; Klausen, Thomas L. ; Loft, Annika ; Kjaer, Andreas ; Madsbad, Sten ; Lofgren, Johan ; Holst, Jens J. ; Wewer Albrechtsen, Nicolai J. / No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. In: Diabetes, Obesity and Metabolism. 2020 ; Vol. 22, No. 10. pp. 1837-1846.

Bibtex

@article{f39b2fa158704bdaa44f590e73c838b7,
title = "No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes",
abstract = "Aim To investigate the effect of a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, on pancreatic volume, oedema, cellularity and DNA synthesis in humans. Materials and Methods We performed an open-label study in 14 obese men (age 38 +/- 11 years, body mass index 32 +/- 4 kg/m(2)) without diabetes. Subjects were examined at baseline, during titration (week 4) of liraglutide towards 3.0 mg/day, and 2 weeks after steady-state treatment (week 6) of a final dose of liraglutide. The primary endpoint was pancreatic volume determined by magnetic resonance imaging. Secondary endpoints included pancreatic oedema and cellularity, positron emission tomography-based [F-18]fluorothymidine (FLT) uptake (DNA synthesis) and plasma pancreatic enzymes. Results Plasma amylase (+7 U/L [95% confidence intervals 3-11],P < .01) and lipase (+19 U/L [7-30],P < .01) increased during liraglutide treatment. Pancreatic volume did not change from baseline to steady state of treatment (+0.2 cm(3)[-8-8],P= .96) and no change in pancreatic cellular infiltration was found (P= .22). During titration of liraglutide, FLT uptake in pancreatic tissue increased numerically (+0.08 [0.00-0.17],P= .0507). Conclusions Six weeks of treatment with liraglutide did not affect pancreatic volume, oedema or cellularity in obese men without diabetes. Keywords",
keywords = "antiobesity drug clinical trial GLP-1 analogue",
author = "Svane, {Maria S.} and Johannesen, {Helle H.} and Christoffer Martinussen and Bojsen-Moller, {Kirstine N.} and Hansen, {Martin Lundsgaard} and Hansen, {Adam E.} and Deacon, {Carolyn F.} and Bolette Hartmann and Keller, {Sune H.} and Klausen, {Thomas L.} and Annika Loft and Andreas Kjaer and Sten Madsbad and Johan Lofgren and Holst, {Jens J.} and {Wewer Albrechtsen}, {Nicolai J.}",
year = "2020",
doi = "10.1111/dom.14106",
language = "English",
volume = "22",
pages = "1837--1846",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes

AU - Svane, Maria S.

AU - Johannesen, Helle H.

AU - Martinussen, Christoffer

AU - Bojsen-Moller, Kirstine N.

AU - Hansen, Martin Lundsgaard

AU - Hansen, Adam E.

AU - Deacon, Carolyn F.

AU - Hartmann, Bolette

AU - Keller, Sune H.

AU - Klausen, Thomas L.

AU - Loft, Annika

AU - Kjaer, Andreas

AU - Madsbad, Sten

AU - Lofgren, Johan

AU - Holst, Jens J.

AU - Wewer Albrechtsen, Nicolai J.

PY - 2020

Y1 - 2020

N2 - Aim To investigate the effect of a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, on pancreatic volume, oedema, cellularity and DNA synthesis in humans. Materials and Methods We performed an open-label study in 14 obese men (age 38 +/- 11 years, body mass index 32 +/- 4 kg/m(2)) without diabetes. Subjects were examined at baseline, during titration (week 4) of liraglutide towards 3.0 mg/day, and 2 weeks after steady-state treatment (week 6) of a final dose of liraglutide. The primary endpoint was pancreatic volume determined by magnetic resonance imaging. Secondary endpoints included pancreatic oedema and cellularity, positron emission tomography-based [F-18]fluorothymidine (FLT) uptake (DNA synthesis) and plasma pancreatic enzymes. Results Plasma amylase (+7 U/L [95% confidence intervals 3-11],P < .01) and lipase (+19 U/L [7-30],P < .01) increased during liraglutide treatment. Pancreatic volume did not change from baseline to steady state of treatment (+0.2 cm(3)[-8-8],P= .96) and no change in pancreatic cellular infiltration was found (P= .22). During titration of liraglutide, FLT uptake in pancreatic tissue increased numerically (+0.08 [0.00-0.17],P= .0507). Conclusions Six weeks of treatment with liraglutide did not affect pancreatic volume, oedema or cellularity in obese men without diabetes. Keywords

AB - Aim To investigate the effect of a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, on pancreatic volume, oedema, cellularity and DNA synthesis in humans. Materials and Methods We performed an open-label study in 14 obese men (age 38 +/- 11 years, body mass index 32 +/- 4 kg/m(2)) without diabetes. Subjects were examined at baseline, during titration (week 4) of liraglutide towards 3.0 mg/day, and 2 weeks after steady-state treatment (week 6) of a final dose of liraglutide. The primary endpoint was pancreatic volume determined by magnetic resonance imaging. Secondary endpoints included pancreatic oedema and cellularity, positron emission tomography-based [F-18]fluorothymidine (FLT) uptake (DNA synthesis) and plasma pancreatic enzymes. Results Plasma amylase (+7 U/L [95% confidence intervals 3-11],P < .01) and lipase (+19 U/L [7-30],P < .01) increased during liraglutide treatment. Pancreatic volume did not change from baseline to steady state of treatment (+0.2 cm(3)[-8-8],P= .96) and no change in pancreatic cellular infiltration was found (P= .22). During titration of liraglutide, FLT uptake in pancreatic tissue increased numerically (+0.08 [0.00-0.17],P= .0507). Conclusions Six weeks of treatment with liraglutide did not affect pancreatic volume, oedema or cellularity in obese men without diabetes. Keywords

KW - antiobesity drug clinical trial GLP-1 analogue

U2 - 10.1111/dom.14106

DO - 10.1111/dom.14106

M3 - Journal article

C2 - 32495988

VL - 22

SP - 1837

EP - 1846

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 10

ER -

ID: 244367695